In vivo assessment of the antipyretic activity of tilmicosin
| Autor: | Abubakr El-Mahmoudy, Shaban Awidat, A. A. Elmajdoub, Ibtsam Gheith |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Pharmacology medicine.drug_class business.industry Antibiotics Pharmaceutical Science Symptomatic relief 03 medical and health sciences Subcutaneous injection chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine chemistry In vivo Tested time medicine Antipyretic Tilmicosin business 030217 neurology & neurosurgery Injectable Solution medicine.drug |
| Zdroj: | African Journal of Pharmacy and Pharmacology. 12:176-182 |
| ISSN: | 1996-0816 |
| DOI: | 10.5897/ajpp2018.4909 |
| Popis: | The aim of the present study was to assess the antipyretic activity of the macrolide antibiotic, tilmicosin, at dose levels of 20 and 40 mg/kg of body weight, subcutaneously, in Brewer's yeast-induced fever model in mice. Pyrexia was induced by subcutaneous injection of 20 mL/kg of 20% (w/v) Brewer’s yeast suspension into the animal’s scruff region. Eighteen hours later, feverish animals were treated with either tilmicosin or acetylsalicylic acid (200 mg/kg injectable solution, subcutaneously) or vehicle; and rectal temperatures were evaluated at 1, 2, 3, 4 and 5 h post-treatment using digital thermometers. Tilmicosin showed dose-dependent significant decrease in the elevated body temperature of mice that remained sustained throughout the tested time points from 1 to 5 h in the used model. Both small and large dose levels showed a significant inhibition of elevated body temperature when compared with the corresponding febrile controls (37.65 ± 0.04 vs. 38.41 ± 0.08°C and 37.44 ± 0.04 vs. 38.44 ± 0.04, after 1 h; 37.19 ± 0.04 vs. 38.41 ± 0.08°C and 36.80 ± 0.03 vs. 38.44 ± 0.04°C after 5 h, respectively). These activities were standardized as 38.0 and 51.59% and 47.9 and 66.43% after 5 h, respectively, compared to that of the standard antipyretic and acetylsalicylic acid (200 mg/kg of body weight, subcutaneously). These results may indicate that tilmicosin, in addition to its well established antibacterial activity, possesses significant antipyretic activity that may be beneficial in symptomatic relief when it is used in therapy of infectious disease conditions and inflammatory disorders. Key words: Antipyretic, tilmicosin, macrolides. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|